Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Privigen for HIV-associated myelopathy
NCT01561755Phase 4Terminated
- Start
- Feb 2012
- Primary completion
- Sep 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of intravenous immunoglobulin G in HIV-associated vacuolar myelopathy (HIV-VM). Primary endpoint: Strength Scores at 2 months. Started Feb 2012; status: terminated.
02
Drugs
intravenous immunoglobulin G
03
Conditions
HIV-associated vacuolar myelopathy (HIV-VM)
Beyond the preview
Go deeper on NCT01561755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01561755.